Skip to content

Study · Not a test of the peptide alone · 2007

2 results

Vasoactive intestinal peptide receptor expression in chronic periapical lesions.

Caviedes-Bucheli J, Azuero-Holguín MM, Moreno GC, González IL, Mateu E, Salazar JF, Munoz HR

International endodontic journal18 May 2007Cited by 4 (Europe PMC)

PMID17511789 (opens in a new tab)DOI10.1111/j.1365-2591.2007.01250.x (opens in a new tab)PepBankPUB-17511789
Source linkPubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone2

In this study, Vasoactive intestinal peptide (VIP, aviptadil) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Vasoactive intestinal peptide (VIP, aviptadil).

  1. 01HumanNot a test of Vasoactive intestinal peptide (VIP, aviptadil) aloneObservational studyMechanism

    In chronic periapical lesions from human teeth, VIP receptors were present in all samples.

    In plain wordsVIP receptors were found in all chronic periapical lesion samples from human teeth.

    Peptide
    Vasoactive intestinal peptide (VIP, aviptadil)
    Outcome
    Not applicableVIP receptor expression in periapical lesions
    Study

    n = 12

    Human chronic periapical lesion samples
    Outcome group
    Receptor activity and mechanism · Immune and inflammation

    Source sentences

    Summary
    Vasoactive intestinal peptide receptor expression was found in all periapical lesion samples.
    1 context sentence
    Summary · context
    Twelve periapical lesions were obtained from teeth diagnosed with chronic apical periodontitis and indicated for endodontic surgery; they were classified according to the size of the lesion in two groups of six samples (lesion size greater or smaller than 5 mm), and then processed and labelled with (125)I-VIP.

    In this study, Vasoactive intestinal peptide (VIP, aviptadil) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Vasoactive intestinal peptide (VIP, aviptadil).

  2. 02HumanNot a test of Vasoactive intestinal peptide (VIP, aviptadil) aloneObservational studyMechanism

    VIP receptor expression was higher in periapical lesions smaller than 5 mm than in larger lesions.

    In plain wordsVIP receptors were more abundant in small periapical lesions (under 5 mm) than in larger ones.

    Peptide
    Vasoactive intestinal peptide (VIP, aviptadil)
    Outcome
    IncreaseVIP receptor expression by lesion size
    Study

    n = 12

    Human chronic periapical lesion samples
    Comparator
    Lesions larger than 5 mm
    Outcome group
    Receptor activity and mechanism · Immune and inflammation

    Source sentences

    Summary
    There was a statistically significantly higher expression in periapical lesions <5 mm (P < 0.001).
    1 context sentence
    Summary · context
    Twelve periapical lesions were obtained from teeth diagnosed with chronic apical periodontitis and indicated for endodontic surgery; they were classified according to the size of the lesion in two groups of six samples (lesion size greater or smaller than 5 mm), and then processed and labelled with (125)I-VIP.

    In this study, Vasoactive intestinal peptide (VIP, aviptadil) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Vasoactive intestinal peptide (VIP, aviptadil).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 12:58 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 12:41 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.